Searchable abstracts of presentations at key conferences in endocrinology

ea0020s22.1 | Tumorigenesis in pheochromocytoma/paraganliomas | ECE2009

The Warburg effect in pheochromocytoma: a link between genetic disorders and cell metabolism

Favier Judith

Tumorigenesis and intermediary metabolism have a long common history. Eighty years ago, the biochemist Otto Warburg pioneered a large field of researches devoted to the metabolism of tumour cells. He reported a spectacular shift from a normal aerobic metabolism to a highly glycolytic metabolism, associated with a low respiration rate, despite aerobic conditions. After being forgotten for decades, a renewed interest in the Warburg effect has resulted from the report that, mitoc...

ea0056s15.3 | EYES: New aspects in the study of neuroendocrine diseases | ECE2018

Epigenetic and metabolic reprogramming of SDH deficient pheochromocytomas and paragangliomas

Favier Judith

SDHA, B, C, and D (SDHx) genes encode the four subunits of succinate dehydrogenase (SDH), a mitochondrial enzyme of the tricarboxylic acid (TCA) cycle that oxidizes succinate into fumarate. They were the first genes encoding a mitochondrial enzyme demonstrated to act as tumor suppressors, an important finding supporting the hypothesis of a direct link between mitochondrial dysfunction and cancer proposed by Otto Warburg in the 1920’s. It is estimated that germline mutatio...

ea0050s5.2 | Beyond paragangliomas | SFEBES2017

Identification of novel therapeutic targets in SDH-mutated cancers: tracing dysfunction

Lussey-Lepoutre Charlotte , Hollinshead Kate E R , Ludwig Christian , Menara Melanie , Morin Aurelie , Gimenez-Roqueplo Anne-Paule , Favier Judith , Tennant Daniel A

Since the discovery of mutations in succinate dehydrogenase (SDH) complex early this century, it has been shown that tumours underpinned by deficiencies in this metabolic enzyme will demonstrate altered cell metabolism. However, the precise nature of these changes remains poorly described. The metabolic network within cells is highly redundant, with multiple pathways capable of synthesising the required building blocks for cell growth. By the very fact that SDH-deficient cells...

ea0050s5.2 | Beyond paragangliomas | SFEBES2017

Identification of novel therapeutic targets in SDH-mutated cancers: tracing dysfunction

Lussey-Lepoutre Charlotte , Hollinshead Kate E R , Ludwig Christian , Menara Melanie , Morin Aurelie , Gimenez-Roqueplo Anne-Paule , Favier Judith , Tennant Daniel A

Since the discovery of mutations in succinate dehydrogenase (SDH) complex early this century, it has been shown that tumours underpinned by deficiencies in this metabolic enzyme will demonstrate altered cell metabolism. However, the precise nature of these changes remains poorly described. The metabolic network within cells is highly redundant, with multiple pathways capable of synthesising the required building blocks for cell growth. By the very fact that SDH-deficient cells...

ea0056oc7.4 | Genomic and clinical aspects of endocrine tumours | ECE2018

Germline mutations in the mitochondrial 2-oxoglutarate/malate carrier (SLC25A11) gene confer predisposition to metastatic paragangliomas

Buffet Alexandre , Morin Aurelie , Castro-Vega Luis-Jaime , Habarou Florence , Lussey-Lepoutre Charlotte , Letouze Eric , Lefebvre Herve , Guilhem Isabelle , Haissaguerre Magalie , Raingeard Isabelle , Padilla-Girola Mathilde , Tran Thi , Tchara Lucien , Bertherat Jerome , Amar Laurence , Ottolenghi Chris , Burnichon Nelly , Gimenez-Roqueplo Anne-Paule , Favier Judith

Integrative genomics studies of paragangliomas (PGL) have shown that PGL susceptibility genes are the main drivers of tumorigenesis. Comprehensive genetic analyses have identified germline SDHB and, to a lesser extent, FH gene mutations, as predominant causes of metastatic PGL. However, some suspicious cases remain unexplained. We performed whole-exome sequencing of a paraganglioma exhibiting an SDHx-like molecular profile in the absence of SDHx<...

ea0063oc5.1 | Adrenal 1 | ECE2019

Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma

Buffet Alexandre , Aim Laurene Ben , Leboulleux Sophie , Drui Delphine , Vezzosi Delphine , Libe Rossella , Ajzenberg Christiane , Bernardeschi Daniele , Cariou Bertrand , Chabolle Frederic , Chabre Olivier , Darrouzet Vincent , Delemer Brigitte , Desailloud Rachel , Goichot Bernard , Esvant Annabelle , Offredo Lucile , Herman Philippe , Laboureau Sandrine , Lefebvre Herve , Pierre Peggy , Raingeard Isabelle , Reznik Yves , Sadoul Jean-Louis , Hadoux Julien , Tabarin Antoine , Tauveron Igor , Zenaty Delphine , Favier Judith , Bertherat Jerome , Baudin Eric , Amar Laurence , Gimenez-Roqueplo Anne-Paule

Context: Paragangliomas and pheochromocytomas (PPGL) are rare neuroendocrine tumors, characterized by a strong genetic component. Indeed, up to 40% of patients carry a germline mutation in a PPGL susceptibility gene. In accordance with the international recommendations, genotyping of PPGL susceptibility genes is therefore proposed to all patients with PPGL, but it has actually never been shown whether the identification of a germline mutation in one PPGL susceptibility gene ch...